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IntroductIon
Alzheimer’s disease (AD) is a neurodegenerative disorder 
characterized by the progressive development of memory 
deficits. AD is neuropathologically defined by extracellular 
accumulation of amyloid-β peptides into amyloid plaques 
and intraneuronal fibrillar aggregates of hyper- and abnor-
mally phosphorylated tau proteins (Masters et al., 1985; Ser-
geant et al., 2008). Tau pathology is observed early in the 
brainstem and entorhinal cortex (Braak et al., 2011), and 
its progression in the cortex from entorhinal cortex to hip-
pocampus to neocortex corresponds to the progression of 
AD symptoms (Duyckaerts et al., 1997; Grober et al., 1999; 
Jucker and Walker, 2013).
Pathways underlying tau pathology–induced synaptic/
cognitive deficits and neurodegeneration are not well un-
derstood. The prevalent hypothesis is that hyperphosphory-
lation, misfolding, and fibrillization of tau (“tau pathology”) 
impair synaptic plasticity and cause degeneration (Wang and 
Mandelkow, 2016), with a large agreement toward a toxic 
gain of function. However, we cannot rule out that tau pa-
thology may also result in the loss of specific physiological 
tau functions that finally contribute to neuronal dysfunc-
tion, but this hypothesis has been poorly investigated (Tro-
janowski and Lee, 2005; Morris et al., 2011). Constitutive 
deletion of tau does not lead to lethality or neurodegen-
eration (Morris et al., 2011; Wang and Mandelkow, 2016), 
presumably because of compensatory mechanisms (Harada 
et al., 1994). However, tau is obviously needed for normal 
brain function, because tau deletion has been associated 
with brain iron accumulation (Lei et al., 2012) and deficits 
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derstood. one prevalent hypothesis is that hyperphosphorylation, misfolding, and fibrillization of tau impair synaptic plasticity 
and cause degeneration. However, tau pathology may also result in the loss of specific physiological tau functions, which are 
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data have far-reaching clinical implications and raise the hypothesis that pathophysiological tau loss-of-function favors brain 
insulin resistance, which is instrumental for cognitive and metabolic impairments in Alzheimer’s disease patients.
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in synaptic plasticity and cognition (Kimura et al., 2014; Ma 
et al., 2014; Ahmed et al., 2015).
There is limited knowledge on the physiological roles of 
tau. The most extensively described neuronal functions of tau 
are related to its ability to bind microtubules, to regulate their 
assembly and spacing, as well as to control axonal transport 
(Dixit et al., 2008; Sergeant et al., 2008; Morris et al., 2011; 
Wang and Mandelkow, 2016; Lacovich et al., 2017). Recently, 
other functions have emerged, such as the ability of tau to 
control neuronal excitability at dendritic spines (Ittner et al., 
2010) or protect nucleic acids from oxidative stress (Sultan et 
al., 2011; Violet et al., 2014). However, as a scaffold protein 
(Arendt et al., 2016), broader tau functions are expected, and 
thus, better knowledge of tau functions is essential to gain 
insight into the pathophysiological processes underlying AD 
and tauopathies. In the present study, we uncover a novel func-
tion of tau in its ability to regulate brain insulin signaling and 
discuss the pathophysiological implications of these findings.
rESultS And dIScuSSIon
tau deletion impairs hippocampal response to insulin
Tau deletion impairs hippocampal synaptic plasticity and 
memory in mice (Kimura et al., 2014; Ma et al., 2014; Ahmed 
et al., 2015), but the underlying mechanisms remain unclear. 
Here, we investigated a potential interaction between tau and 
hippocampal insulin signaling, which is known to regulate 
hippocampal plasticity and reference memory (Fernandez and 
Torres-Alemán, 2012; De Felice and Benedict, 2015; Grillo et 
al., 2015). We first addressed the impact of tau deletion upon 
hippocampal responsiveness to insulin using hippocampal 
slices from tau KO mice (Tucker et al., 2001). We evaluated 
insulin-induced hippocampal long-term depression (LTD; 
Van Der Heide et al., 2005) by taking advantage of an induc-
tion protocol, which uses a 30-min incubation with 1 µM 
insulin to evoke LTD of extracellular field excitatory postsyn-
aptic potentials (fEPSPs). As shown in Fig. 1 A, in WT mice, 
insulin induced a marked decay of recordings (47.9 ± 7.2%) 
compared with baseline (240 min; P = 0.0011 vs. baseline). 
Interestingly, in tau KO mice, the magnitude of hippocam-
pal LTD was significantly reduced compared with littermate 
controls (240 min, slope at 87.5 ± 12.1% of baseline, 1–240 
min, P < 0.001 vs. WT, two-way ANO VA; Fig. 1 A). Impaired 
insulin responsiveness was confirmed in another set of exper-
iments that revealed a significant reduction of hippocampal 
Akt ex-vivo phosphorylation, after insulin application to slices 
(Fig. 1 B), but also in vivo, after intracerebroventricular (icv) 
injection of the hormone (Fig. 1 C). These data support that 
tau deletion leads to hippocampal insulin resistance. To test 
whether tau overexpression was, conversely, associated with 
improved response to insulin, we used a model of N1E115 
neuroblastoma cells that overexpress WT 1N4R human tau 
(Fig. 1 D), in the absence of tau aggregation (Fig. 1 E). In 
this model, we observed a higher responsiveness to insulin 
treatment in neuroblastoma N1E115 cells overexpressing 
hTau than in controls (Fig. 1 F). Altogether, the present data 
support the ability of tau to modulate hippocampal respon-
siveness to insulin and open the possibility that tau itself reg-
ulates insulin signaling.
Interaction between tau and insulin signaling
Next, we aimed to understand the mechanisms underly-
ing the ability of tau to modify the response to insulin. In a 
first attempt, we evaluated whether insulin-induced tyrosine 
phosphorylation of insulin receptor (IR) could be modified 
after tau deletion. Compared with respective littermate con-
trols, tyrosine phosphorylation of IRs remained unaffected by 
tau deletion after insulin application to slices (Fig. 2 A). Fur-
ther, IR membrane expression remained unaffected by hTau 
overexpression in neuroblastoma cells (not depicted).
Next, we investigated the impact of tau deletion upon 
IRS-1, which is an important node of insulin signaling. Ty-
rosine phosphorylation of IRS-1 by IR leads to the down-
stream activation of Akt, whereas the phosphorylation of 
IRS-1 on multiple serine residues inhibits IRS-1 activity, 
leading to insulin resistance (Copps and White, 2012). Several 
works notably associated abnormal IRS-1 serine phosphor-
ylation to brain insulin resistance in the context of AD and 
tauopathies (Ma et al., 2009; Bomfim et al., 2012; Talbot et 
al., 2012; Yarchoan et al., 2014). Here, we found that insu-
lin-induced hippocampal tyrosine phosphorylation of IRS-1 
was reduced in tau KO mice after slice treatment (Fig. 2 B) 
or after icv injection with the hormone (Fig.2 C). In line 
with an impairment of IRS-1 activity, we also observed that 
serine phosphorylation at Ser636 was increased in the hippo-
campus of tau KO animals (Fig. 2 D). Serine phosphorylation 
of IRS-1 has been suggested to be related to a bottom-up 
(rather than top-down) effect involving downstream kinases 
such as JNK (Ma et al., 2009). This fits well with the previ-
ously demonstrated JNK activation in tau KO mice (Ma et al., 
2014). This is also in line with the idea that phosphorylated 
serines/threonines of IRS-1 could inhibit its tyrosine phos-
phorylation (Mothe and Van Obberghen, 1996). Together, 
the present data thus support that tau deletion is associated 
with impaired IRS-1 function. Tau KO mice exhibit changes 
reminiscent of the AD brain; that is, a concomitant reduction 
of insulin-induced IRS-1 tyrosine phosphorylation (Talbot 
et al., 2012) with an increased IRS-1 phosphorylation at 
Ser636 (Bomfim et al., 2012).
Further, we performed coimmunoprecipitation experi-
ments in neuroblastoma N1E115 cells expressing WT hTau to 
evaluate whether tau interacts with elements controlling insu-
lin signaling (Fig. 2 D). Tau did not interact with IR or IRS-1 
(Fig. 2 E). Although previous biochemical studies suggested 
that tau may bind to the p85α subunit of phosphoinositide 
3-kinase (PI3K; Reynolds et al., 2008), we did not observe 
coimmunoprecipitation of PI3K (p85) with tau (Fig. 2 E). As 
our results indicate that tau deletion blunts the response to 
insulin, we also addressed a possible interaction of tau with 
three phosphatases known to inhibit insulin signaling: protein 
tyrosine phosphatase 1B (PTP1B), SH2 domain containing 
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inositol 5-phosphatase 2 (SHIP2), and phosphatase and tensin 
homologue on chromosome 10 (PTEN). Although tau did 
not interact with PTP1B and SHIP2 (Fig. 2 E), we found it 
coimmunoprecipitated with PTEN in WT hTau-transfected 
N1E115 cells (Fig.  3  A) and also in mouse brain tissue 
(Fig. 3 B). A direct interaction between WT hTau and PTEN 
was further confirmed using the bimolecular fluorescence 
complementation (BiFC) assay (Fig. 3 C). PTEN is known 
as a negative regulator of the PI3K-Akt pathway and, using in 
vitro and bioluminescence resonance energy transfer (BRET) 
experiments, we found that PTEN activity and cellular 
PtdIns(3,4,5)P3 production were dependent on tau. First, 
we demonstrated that recombinant WT hTau impaired the 
lipid phosphatase activity of recombinant PTEN by decreas-
ing PtdIns(3,4,5)P3 dephosphorylation into PtdIns(4,5)P2 in 
cell-free conditions (Fig. 3 D). In addition, using an in cellulo 
BRET assay (Pierre-Eugene et al., 2012), we measured that 
expression of tau not only was sufficient to favor PtdIns(3,4,5)
P3 formation in N1E115 cells by itself but also potentiated 
the enhancing effects of insulin on PtdIns(3,4,5)P3 formation 
(Fig. 3 E). Altogether, the present data unravel the ability of 
tau to reduce PTEN activity and to favor PtdIns(3,4,5)P3 
Figure 1. tau regulates hippocampal response to insulin. (A) Hippocampal LTD induced by 1 µM insulin (30 min) in tau KO and WT mice. Each point 
represents mean ± SEM normalized to baseline values preceding the application of insulin (***, P < 0.001, two-way ANO VA). (B) Akt phosphorylation in 
hippocampal slices from tau KO mice and littermate controls, 10 min after 200 nM insulin treatment (*, P < 0.05, Student’s t test). (C) Akt phosphorylation in 
the hippocampus of tau KO mice and littermate controls, 1h after an icv injection of 2 µl at 5 mg/ml insulin (*, P < 0.05, Student’s t test). Tau KO mice were 
7–12 mo old. (D) hTau expression and phosphorylation and (E) hTau detection in sarkosyl-soluble and -insoluble fractions from N1E115 cells overexpressing 
WT 1N4R human tau isoform. (F) Akt phosphorylation in N1E115 overexpressing WT hTau or transfected by empty vector, 10 min after insulin treatment 
at 200 nM (*, P < 0.05, Student’s t test). Controls are indicated as open circles/bars and tau KO/overexpressing cells as black circles/bars. Data in A–C show 
mean ± SEM from six (A), six to eight (B), and six or seven (C) mice per group from six (A), two (B), or three (C) independent experiments. Data in D and E 
show results from one independent experiment. Data in F show mean ± SEM from eight wells per group from five independent experiments. Ins, insulin. 
Molecular mass is indicated in kilodaltons.
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production, explaining, apart the aforementioned effect to-
ward IRS-1, the reduced insulin responsiveness seen in condi-
tions where tau is deleted (Fig. 1; Ortega-Molina and Serrano, 
2013). Therefore, our data indicate that interaction between 
tau and PTEN restrains PTEN’s lipid phosphatase activity, 
favoring pro-cognitive insulin signaling. Interestingly, PTEN 
has been shown to contribute instrumentally to the memory 
alterations in mouse models of AD (Knafo et al., 2016), sup-
porting a critical role of this phosphatase in the regulation of 
hippocampal synaptic plasticity. However, the precise identifi-
cation and characterization of tau functions, whose loss leads 
to insulin resistance in AD, is left to further research.
tau deletion inhibits anorexigenic effect of brain insulin 
administration and leads to metabolic disturbances
Considering the broad functions of insulin signaling in the 
adult brain (Fernandez and Torres-Alemán, 2012), we as-
sumed that its regulation by the pan-neuronal tau protein 
might not be restricted to hippocampus. Thus, we next asked 
whether constitutive tau deletion in mice would modulate 
the known ability of intracerebroventricularly administered 
insulin (bilateral icv injection in lateral ventricle) to reduce 
food intake and body weight gain (Woods et al., 1979; Brown 
et al., 2006). As expected, 24-h food intake was significantly 
reduced in WT littermate animals after icv insulin adminis-
tration (Fig.  4 A). Strikingly, the anorexigenic effect of icv 
insulin was strongly reduced in tau KO mice (Fig. 4, A and 
B). Accordingly, icv insulin was able to promote body weight 
loss in WT, but not tau KO, mice (Fig. 4 C). These data indi-
cated that brain insulin signaling is blunted in tau KO mice. 
Impaired insulin response was not associated with impaired 
response to leptin. Indeed, as expected, 3-d intraperitoneal 
leptin injections reduced food intake and body weight in WT 
littermate animals by 27.3 ± 6.6% (four replicates, P = 0.02) 
and 3.8 ± 0.4% (four replicated, P = 0.002), respectively. Sim-
ilar changes were observed in tau KO animals (−21.3 ± 6.4% 
and −3.8 ± 0.5%, four replicates), suggesting that leptin sen-
sitivity remained unaffected by tau deletion.
Figure 2. Impact of tau deletion upon Ir and IrS-1. (A) IRs from hippocampal slice extracts (400 µg protein) were precipitated on wheat-germ lectin 
(WGL) agarose beads, eluted with Laemmli sample buffer, and submitted to SDS-PAGE followed by Western blotting. Insulin-induced phosphorylation of 
the IR on the three tyrosines of the kinase domain was evaluated using anti–IRpY1158-1162-1163 antibody. The amount of IR present in each track was 
evaluated by reprobing the membrane with an anti-IRβ antibody. (B) Tyrosine phosphorylation of IRS-1 in hippocampal slices from tau KO mice and litter-
mate controls 10 min after 200 nM insulin treatment (*, P < 0.05, Student’s t test). Total IRS-1 remains constant. (C) Tyrosine phosphorylation of IRS-1 in 
the hippocampus of KO tau mice and littermate controls 1 h after icv injection of 2 µl insulin at 5 mg/ml (*, P < 0.05, Student’s t test). Total IRS-1 remains 
constant. (D) Serine phosphorylation of IRS-1 in tau KO mice and littermate controls. (*, P < 0.05, Student's t test). (E) Coimmunoprecipitation experiments 
between hTau and different members of the insulin-signaling pathway in N1E115 cells transfected with WT 1N4R hTau. Tau interacted with PTEN only 
(Fig. 3 A). Ø indicates negative control of immunoprecipitation (IP; without primary antibody; only mouse anti-IgG beads); Ab indicates immunoprecipita-
tion with the primary antibody and mouse anti-IgG beads. Unbound indicates the immunoprecipitation supernatant samples, whereas eluate indicates the 
immunoprecipitation complexes. Controls are indicated as open bars and tau KO animals as black bars. KO mice were 7–12 mo old. Data in A–D show mean 
± SEM from four (A), three (B), three (C), and five (D) mice per group from two independent experiments. Coimmunoprecipitations were obtained from at 
least two independent experiments. Molecular mass is indicated in kilodaltons.
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Both genetic deletion of neuronal IRs and hypotha-
lamic IR knockdown have been previously shown to in-
crease food intake, body weight gain, and adiposity in rodents 
(Brüning et al., 2000; Obici et al., 2002; Grillo et al., 2007). 
In accordance with impaired insulin signaling in the brain of 
tau KO mice, we found that the latter exhibited enhanced 
food intake when fed ad libitum (Fig. 4, A and D) and body 
weight gain when compared with WT littermates (Fig. 4 F) 
in the absence of a change in body weight at weaning (Fig. 
S1 A). Adiposity was increased in tau KO mice, as exempli-
fied by enhanced circulating leptin (Fig.  4 G) and adipose 
tissue weight (Fig. 4, H and I). Furthermore, tau deletion was 
also associated with a significant hyperinsulinemia (Fig. 4 K) 
and glucose intolerance (Fig. 4 L). As shown in Fig. S2, tau 
heterozygous mice, whose brain tau expression was reduced 
when compared with WT littermates (Fig. S2 I), exhibited a 
metabolic phenotype in-between WT and tau KO mice, par-
ticularly regarding food intake and glucose tolerance (Fig. S2, 
A–H). When combined, these data indicate that the neuronal 
protein tau plays an important role in the regulation of en-
ergy homeostasis and peripheral metabolism. The metabolic 
changes seen in tau KO mice are likely caused by the inability 
of the hypothalamus to properly respond to insulin. However, 
the contribution of peripheral tau to the metabolic changes 
observed is also possible. Indeed, tau mRNA expression has 
been found in normal human exocrine pancreas (Neuville et 
al., 1995), and tau protein has been shown to colocalize with 
insulin-positive β-cells at the islets of Langerhans of pancre-
atic tissue from tumor resections (Maj et al., 2010). Further, 
expression of tau in insulinoma cells transiently reduces in-
sulin secretion, whereas expression or knockdown of tau in 
rat insulinoma cells leads to increased or decreased insulin 
Figure 3. tau interacts with PtEn and modulates its lipid phosphatase activity. (A and B) Coimmunoprecipitation of hTau (WT 1NR4) overexpressed 
in N1E115 cell (A) and mouse tau in the hippocampus of WT mice (B) with PTEN. Data are representative of two independent experiments from independent 
samples. (C) Bimolecular fluorescence complementation (BiFC) assay confirms the interaction between WT 1N4R tau and PTEN in the cytoplasm of HEK-293 
cells. Data are representative of three independent experiments (***, P < 0.001 vs. VN-PTEN; one-way ANO VA, LSD Fisher’s post-hoc test). Bars, 30 μm. (D) 
In cell-free conditions, lipid phosphatase activity of PTEN is decreased in the presence of recombinant hTau protein (control, open circles; WT 1N4R, black 
circles; ***, P < 0.001, two-way ANO VA). Note that PTEN activity is not modulated in the presence of an irrelevant protein (albumin; not depicted). Data 
show mean ± SEM from six to eight assays per condition from three independent experiments. (E) Modulation of PtdIns(3,4,5)P3 production by hTau (WT 
1N4R) using BRET. In each experiment, delta BRET was determined by removing mean basal BRET values from mean BRET values obtained for each experi-
mental condition (20 BRET measurements per experimental condition). Inset: typical BRET experiment showing real-time insulin effect on PIP3 production 
is presented (open circle, control/vehicle; closed circles, hTau/vehicle; open square, control/insulin; closed square, hTau/insulin; *, P < 0.05; ***, P < 0.001 
vs. control; #, P < 0.05 vs. insulin condition; one-way ANO VA, LSD Fisher’s post-hoc test). Data show mean ± SEM from five assays per condition from two 
independent experiments. Molecular mass is indicated in kilodaltons.
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transcription in the same cells, respectively (Maj et al., 2016). 
Therefore, these data support a role of tau in the regulation 
of insulin transcription and secretion by insulinoma cancer 
cells (although this has not been demonstrated in primary 
β-cells). We thus cannot rule out that the effect of tau deletion 
upon insulin levels or glucose tolerance is the consequence 
of pancreatic regulations. Interestingly, increased body weight 
gain and adiposity of tau KO mice (Fig. 4, F, H, and I) was 
also associated with a reduced ambulatory activity. The rela-
tionship between insulin signaling and motor function has 
been poorly documented in the literature. However, Mysoet 
et al. (2017) have recently shown that the cortical administra-
tion of IGF-1, a protein that is structurally similar to insulin 
and shares a similar signaling pathway, induces an increase in 
motor activity of rats. Other recent data point to a correlation 
between insulin resistance and disease severity in spinal and 
bulbar muscular atrophy (Nakatsuji et al., 2017), supporting a 
role of peripheral metabolic alterations and muscle function. 
Figure 4. tau deficiency inhibits an anorexigenic effect of brain insulin administration leading to metabolic disturbances. (A) Cumulative food 
intake for 24 h measured using metabolic cages in tau KO and littermate controls intracerebroventricularly injected first with vehicle and then 2 µl insulin 
(5 mg/ml; ***, P < 0.001 vs. WT-PBS; °°°, P < 0.001 vs. tau KO/insulin; two-way ANO VA). (B) Cumulated food intake in WT and tau KO mice 24 h after vehicle 
or insulin brain injection (same animals as in A; *, P < 0.05; **, P < 0.01 vs. WT-PBS; #, P < 0.05 vs. WT/insulin; °°°, P < 0.001 vs. tau KO/insulin; one-way 
ANO VA, LSD Fisher’s post-hoc test). (C) 48-h body weight variation after vehicle or insulin brain injection in tau KO and WT littermates (same animals as in 
A; °°°, P < 0.001 vs. tau KO/insulin; two-way ANO VA). Data in A–C show mean ± SEM from 5–10 mice per group from three independent experiments. (D) 
Mean food intake (*, P < 0.05, two-way ANO VA). (E) Ambulatory activity (*, P < 0.05, two-way ANO VA). (F) Body weight gain (***, P < 0.05, two-way ANO VA). 
(G) Plasma leptin levels (**, P < 0.01, Student’s t test). (H and I) Adipose tissue weight (*, P < 0.05; **, P < 0.01, Student’s t test). (J) Glycemia. (K) Insulinemia 
(*, P < 0.05, Student’s t test). (L) Intraperitoneal glucose tolerance test (***, P < 0.05, two-way ANO VA) in tau KO mice and littermate controls. Quantifications 
represent mean ± SEM. Controls are indicated as open circles/bars, tau KO as black circles/bars. Dashed lines/bars represent insulin-treated animals. Mice 
were 6–8 mo old at time of experiments and sacrifice. Metabolic data in C–L show mean ± SEM from 10–12 (D), 9–12 (E), 13–27 (F), 4–5 (G), 11–14 (H and 
I), 15–17 (J), 20–23 (K), and 12–14 (L) mice per group acquired from three independent experiments.
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It is thus possible that defective insulin signaling in tau KO 
mice leads to impaired motor activity. This is in line with 
previous data (Lei et al., 2012) but remains a matter of de-
bate (Morris et al., 2013).
tau haplotypes are associated with 
glycemic traits in humans
To address whether tau impacts peripheral metabolism in 
humans, we explored the potential association between mi-
crotubule-associated protein tau (MAPT; tau) haplotypes and 
metabolic traits using published genome-wide association 
study (GWAS) data. Although the precise impact remains 
subject to debate, MAPT haplotypes are thought to be as-
sociated with functional changes in the tau protein (Trab-
zuni et al., 2012). Meta-analysis of 21 GWASs indicated that 
the MAPT H1/H2 tagging single-nucleotide polymorphism 
(SNP) rs1052553 was not associated with fasting glucose (P = 
0.42) or fasting insulin (P = 0.79; 46,186 nondiabetic partic-
ipants; Table 1; Dupuis et al., 2010). However, among GWASs 
with oral glucose tolerance test results, the rs1052553 A al-
lele (which captures the H1 haplotype) was associated with 
a higher 2-h glucose level (β = 0.096 mmol/L, P = 0.00006, 
n = 15,234 nondiabetic participants; Saxena et al., 2010) and 
a lower 30-min insulin secretion (β = −0.063 pmol/L, P = 
0.035, n = 5,318 nondiabetic participants; Prokopenko et al., 
2014). These data are in agreement with glucose intolerance 
observed in heterozygous and tau KO mice (Fig. 4 L and Fig. 
S2 G). In line with a metabolic role for tau, a previous GWAS 
found a significant association between the locus 17q21.31 
containing MAPT and food addiction (Cornelis et al., 2016).
concluding remarks
Physiological functions of tau are largely unknown. The pres-
ent data demonstrate a new role for tau in its ability to reg-
ulate brain insulin signaling (Fig. S3). Our data particularly 
indicate that tau deletion not only impairs insulin-induced 
hippocampal plasticity but also blunts the anorexigenic effect 
of this hormone. These observations are particularly inter-
esting in the physiopathological context of AD and tauop-
athies. Indeed, brain insulin resistance is a cardinal feature 
of the AD brain (Moloney et al., 2010; Liu et al., 2011; de 
la Monte, 2014; Stanley et al., 2016a). Postmortem brains 
from AD patients exhibit a reduced responsiveness to insu-
lin, which is correlated with memory deficits (Talbot et al., 
2012). Although a few studies support the involvement of Aβ 
oligomers as a potential trigger for neuronal insulin resistance 
(Zhao et al., 2008; De Felice, 2013; Clarke et al., 2015; but 
see the results recently discussed by Stanley et al., 2016b), 
the role of tau remained completely unknown. Interestingly, 
other data emphasize brain insulin resistance in postmortem 
brains of patients with tauopathies (Yarchoan et al., 2014), 
indeed opening to a presumable role for tau itself.
Pathways underlying tau pathology-induced neuronal 
dysfunctions are not well understood. Pathological tau species 
are generally seen as the trigger for synaptic and cognitive 
impairments (Wang and Mandelkow, 2016). Hippocampal in-
sulin signaling is recognized to favor plasticity and memory 
(Fernandez and Torres-Alemán, 2012; De Felice and Bene-
dict, 2015; Grillo et al., 2015), a concept evidenced in hu-
mans by the ability of intranasal administration of insulin to 
improve cognition of AD patients (Reger et al., 2008; Stan-
ley et al., 2016a). By showing that tau deletion blunts hippo-
campal response to insulin, our data support the possibility 
that impaired tau function could also contribute to abnormal 
plasticity seen in AD and tauopathies. This is in line with the 
observations of defective synaptic regulation and cognition 
in tau KO mice (Kimura et al., 2014; Ma et al., 2014; Ahmed 
et al., 2015). Thus, phenotypes observed in the tau KO mice 
are reminiscent of dysfunctions observed in AD and related 
tauopathies. Altogether, our data further suggest that tau is 
more than a microtubule-associated protein. In fact, tau is a 
scaffold protein (Arendt et al., 2016) that has been involved in 
the signal transduction of Src-family tyrosine kinases (Ittner 
et al., 2010; Burnouf et al., 2013), cyclin-dependent kinases 
(Vincent et al., 1996; Hamdane et al., 2005), and insulin sig-
naling. Thus, impaired physiological tau function is prone to 
impact on signal transduction in neurons and contribute to 
plasticity alterations.
Besides the hippocampus, our data indicate that regu-
lation of insulin signaling by tau also involves the hypothala-
mus, a known brain target of insulin. Our experimental data 
demonstrate that the anorexigenic effect of insulin (Woods 
et al., 1979; Brown et al., 2006) is lost in tau KO mice, but 
combined with human genetic studies (Table  1), our data 
particularly show that tau regulates energy homeostasis and 
peripheral metabolism. The incidence of type 2 diabetes is 
higher in AD patients (Janson et al., 2004). Moreover, in line 
with the occurrence of hypothalamic dysfunction in AD 
Table 1. GWAS meta-analysis assessing the impact of MAPt haplotypes on glycemic traits in European individuals
Variable N Beta SE P Reference
Fasting glucose (mmol/liter) 46,186 0.004 0.005 0.42 Dupuis et al., 2010
Fasting insulin (pmol/liter) 46,186 −0.001 0.005 0.79 Dupuis et al., 2010
2-h glucose (after OGTT) adjusted for BMI (mmol/liter) 15,234 0.096 0.024 5.9E-05 Saxena et al., 2010
30-min insulin secretion (after OGTT, ln) adjusted for BMI (pmol/liter) 5,318 −0.063 0.030 0.035 Prokopenko et al., 2014
Data were downloaded from www .magicinvestigators .org. Specific regression coefficients (beta) and standard error (SE) represent changes in the variable per copy of the rs1052553 A major 
allele (H1 haplotype, frequency = 0.79). Trait values for fasting insulin and insulin secretion 30 min after an oral glucose tolerance test (OGTT) were naturally log transformed (ln). Results 
are adjusted for age, sex, study-specific covariates, and body mass index (BMI) where indicated. N, sample size.
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(Ishii and Iadecola, 2015), affected individuals exhibit fasting 
hyperglycemia and hyperinsulinemia as well as impaired glu-
cose metabolism (Craft et al., 1992, 1998; Meneilly and Hill, 
1993; Razay and Wilcock, 1994; Ma et al., 2016). Therefore, 
brain insulin resistance might be a crucial pathological mech-
anism that interactively drives, and is part of, the progression 
causing the cognitive and metabolic dysfunctions seen in AD 
patients. Impact of peripheral metabolic disturbances on AD 
has been commonly evaluated and experimental data confirm 
the detrimental effects of obesity, insulin resistance, and type 
2 diabetes (T2D) toward β-amyloid and tau lesions as well as 
associated cognitive impairments (Takeda et al., 2010; May-
eux and Stern, 2012; Papon et al., 2013). Our data support a 
mutual pathophysiological relationship. Indeed, tau deletion 
leads to the development of peripheral metabolic abnormal-
ities, in line with metabolic impairments seen in AD patients 
(Craft et al., 1992; Meneilly and Hill, 1993; Razay and Wil-
cock, 1994; Turner et al., 2013). Impaired tau function could 
therefore contribute to metabolic changes seen in AD pa-
tients. Overall, our data support the existence of a detrimen-
tal vicious circle linking peripheral metabolism dysregulations 
and lesion development in AD.
Altogether, our data demonstrate a novel physiological 
function of tau protein in the control of brain insulin signal-
ing that could contribute to cognitive and metabolic alter-
ations in patients with AD and tauopathies.
MAtErIAlS And MEtHodS
Animals
Tau KO mice (C57BL6/J background) were generated by 
integrating GFP-encoding cDNA into exon 1 of the mouse 
MAPT gene (Tucker et al., 2001). In all experiments, only 
males were used. All animals were maintained in standard 
animal cages under conventional laboratory conditions 
(12-h/12-h light/dark cycle, 22°C), with ad libitum access 
to food and water. The animals were maintained in compli-
ance with European standards for the care and use of labo-
ratory animals and experimental protocols approved by the 
local Animal Ethical Committee (agreement APA FIS#2264-
2015101320441671 from CEEA75, Lille, France).
Hippocampal slices preparation
Mice were killed by cervical dislocation. Whole brains were 
rapidly removed from the skull and immersed for 1 min in 
ice-cold artificial cerebrospinal fluid (ACSF) solution con-
taining (mM): 117 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgCl2, 1.2 
NaH2PO4, 25 NaHCO3, and 10 glucose. The ACSF was con-
tinuously oxygenated with 95% O2, 5% CO2 to maintain the 
proper pH, 7.4. The hippocampi were quickly removed and 
placed into ice-cold ACSF. Thereafter, 400-µm-thick trans-
verse slices were prepared at 4°C with a chopper (McIlwain 
Tissue Chopper, TC752). Slices were then placed in a hold-
ing chamber containing oxygenated ACSF and kept at room 
temperature for at least 1 h before processing. Slices from KO 
tau strain were used either for electrophysiological recordings 
(see next section) or for biochemical experiments. In the lat-
ter case, slices were treated 10 min with 200 nM insulin.
Electrophysiological recordings
Three to five slices were transferred into a custom-made 
submerged-type recording chamber and maintained at 32°C 
constantly superfused with oxygenated ACSF (95% O2, 5% 
CO2) at a rate of 2.5 ml/min. After an incubation time of 
90 min, fEPSPs were evoked in the stratum radiatum of the 
CA1 region by electrical stimulation of Schaffer collater-
al-commissural fibers using ACSF-filled glass micropipettes 
(2–5 MΩ). For stimulation, 100-µs biphasic constant-current 
square pulses were generated by an A-M Systems isolated 
pulse stimulator 2100 and delivered at a frequency of 0.033 
Hz using a tungsten electrode with a 50-µm exposed tip. Sig-
nals were recorded and amplified with an A-M Systems 1700 
differential amplifier (bandpass filtered at 5 Hz and 10 kHz, 
respectively), digitized using a CED 400 micro AD-converter; 
Cambridge Electronic Devices), and then further analyzed 
on-line using custom-made software. To analyze synaptic 
transmission efficiency, input/output curves were constructed 
by applying single stimuli in increments of 10 µA from 0 
to 90 µA. For subsequent experiments, the intensity of the 
stimulation was adjusted to elicit a fEPSP of 35% of the max-
imum and was kept constant throughout the experiment. In 
all experiments, baseline synaptic transmission was monitored 
for 30–60 min before drug administration. All values from the 
onset of insulin application until the end of recording were 
expressed relative to the control level (percentage of baseline).
Surgical procedures and injections
Bilateral cannulae (C235G-3.0/SPC with a removable dummy 
wire; Plastics One) were stereotaxically implanted into lateral 
ventricle (coordinates with respect to bregma: −0.7 mm an-
teroposterior, ±1.5 mm mediolateral, −2 mm dorsoventral, 
according to the Paxinos and Franklin (2013) in anesthetized 
mice (1.5% isoflurane). Animals were allowed to recover for 1 
wk. Over the next 15 d, animals were habituated to the con-
tention and injection procedure. Injections were performed in 
awake and freely moving mice. Animals were injected with 1 μl 
(per ventricle) of a solution containing either vehicle (PBS, pH 
7.5) or 5 mg/ml insulin at the rate of 0.4 µl/min via cannulae 
PE50 tubing (Plastics One) connected to a 10-µl Hamilton 
syringe pump system (KDS310; KD Scientific). The tubing was 
left in place for another 1 min at the end of each injection and 
the cannulae capped to prevent reflux of the injected solution. 
In metabolic cage experiments, icv injection of insulin took 
place 1  h after light extinction. In experiments where the 
effects of icv insulin toward IRS-1 and Akt phosphorylations 
were evaluated, insulin was injected in nonfasted animals and 
mice sacrificed 1 h after injection. Regarding the in vivo leptin 
sensitivity measurement, three intraperitoneal injections of 3 
mg/kg leptin were made (in 5 mM sodium citrate buffer, pH 
4.0) at 18:00 for 3 d, and body weights and food intake were 
measured as described previously (Coupé et al., 2012).
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cell culture
N1E-115 mouse neuroblastoma cells were grown in Dulbec-
co’s modified Eagle’s medium supplemented with 10% fetal 
calf serum without pyruvate, 2 mM l-glutamine, and 50 U/ml 
penicillin/streptomycin (Invitrogen) in a 5% CO2 humidi-
fied incubator at 37°C. Transfection with plasmid constructs 
(pcDNA4, empty of containing 1N4R human tau sequence) 
was performed 24 h after cell seeding into six-well plates (for 
biochemical studies) using ExGen500 (Euromedex), accord-
ing to the manufacturer’s instructions, for 48 h. When appro-
priate, cells were treated for 10 min with 200 nM insulin.
Biochemical analysis
Proteins from slices were extracted in RIPA buffer (10 mM 
Tris-HCl, 320 mM sucrose, 150 mM NaCl, NP-40 1%, so-
dium deoxycholate 0.5%, and SDS 0.1%, pH 8.0) for West-
ern blot analysis from slices. Protein amounts were evaluated 
using the BCA assay (Thermo Fisher Scientific), subse-
quently diluted with LDS 2× supplemented with reducing 
agents (Invitrogen), and then separated on NuPAGE Novex 
gels (Invitrogen). Proteins were transferred to nitrocellulose 
membranes, which were then saturated (5% nonfat dry milk 
or 5% BSA) in Tris 15 mmol/L, pH 8, NaCl 140 mmol/L, 
and 0.05% Tween and incubated with primary and secondary 
antibodies. Signals were visualized using chemiluminescence 
kits (ECL; GE Healthcare) and a LAS3000 imaging system 
(Fujifilm). Results were normalized to β-actin, and quanti-
fications were performed using ImageJ software (Scion Soft-
ware). β-Actin or GAP DH served as a loading control. For 
immunoprecipitation experiments, extraction was realized 
in a buffer composed of 50 mM Tris-HCl, pH7.4, 150 mM 
NaCl, 1 mM EDTA, 1% Nonidet, and 0.5% sodium deoxy-
cholate with protease inhibitors and samples centrifuged at 
12,000 g (10 min, 4°C). 200 μg supernatant protein was in-
cubated with antibodies targeting tau (tau5, AHB00429; In-
vitrogen) or PTEN (Ab70326; Abcam) and anti-IgG mouse 
beads (TrueBlot; eBioscience) for one night at 4°C. Unbound 
fraction was obtained in the supernatant after a centrifugation 
at 2,000 g (5 min) and the eluate recovered in the pellet after 
three centrifugations at 2,000 g (5 min).
Antibodies used for Western blots were as follows. Anti-
bodies against Akt (#9272), pSer473-Akt (#9271), IR β 
(#3025), pSer616IRS-1 (#3203), pSer636IRS-1 (#2388), 
PI3K-P85 (#4292), PTEN (#9552), PTP1B (#5311) and 
SHIP2 (#2730) were from Cell Signaling Technologies. Anti- 
pY612 IRS-1 was from Thermo Fisher Scientific (44-816G). 
Anti–IRS-1 was from EMD Millipore (06–248). β-Actin was 
from Sigma-Aldrich (A5441), GAP DH was from Santa Cruz 
Biotechnology (FL-1-335). Anti–total tau was a homemade 
antibody (Cter) recognizing the last 15 amino acids of the C 
terminus. Anti–tau pSer396, pSer404, and pSer262 were from 
Invitrogen (44752G, 44758G, and 44750G).
To evaluate the phosphorylation of IR, hippocampal 
slices from tau KO mice and littermate controls were treated 
for 10 min with 200 nM insulin and then frozen in liquid 
nitrogen for subsequent analysis. Proteins were extracted in 
buffer containing 50 mM Tris, pH 8, 137 mM NaCl, 10% glyc-
erol, 1% NP-40, protease inhibitors (1 µg/ml each: 4-(2-am-
inoethyl)benzenesulfonyl fluoride hydrochloride, leupeptin, 
aprotinin, antipain, and pepstatin), and phosphatases inhibi-
tors (50 mM NaF, 10 mM β-glycerophosphate, and 1 mM 
orthovanadate). Precipitation of the IR on wheat-germ lectin 
agarose beads (wheat-germ lectin eluate) was performed as 
described previously (Issad et al., 1995) and analyzed by West-
ern blotting using anti–IRpY1158-1162-1163 antibody (Invitrogen) 
and anti–IRβ antibody (Santa Cruz Biotechnology, Inc.).
Gene expression analysis
Visceral adipose tissue total RNA was isolated using the 
guanidinium isothiocyanate phenol/chloroform extraction 
method. 1 μg total RNA was reverse transcribed to cDNA 
using the high-capacity cDNA reverse transcription kit 
(Applied Biosystems) according to the manufacturer’s in-
structions. Reverse-transcribed cDNAs were quantified by 
Brilliant III Ultra-Fast SYBR green-based real-time PCR 
using specific oligonucleotides (cyclophilin: forward, 5′-GCA 
TAC GGG TCC TGG CAT CTT GTCC-3′; reverse, 3′-ATG 
GTG ATC TTC TTG CTG GTC TTGC-5′; leptin: forward, 
5′-GGT GTG AAA GAA CCT GAG CTG AGG-3′; reverse, 5′-
CAG TGG ATG CTA ATG TGC CCTG-3′) on a Stratagene 
Mx3005P (Agilent Technologies) apparatus. mRNA levels 
were normalized to cyclophilin A expression as an internal 
control, and mRNA fold induction was calculated using the 
comparative Ct (2−ΔΔCt) method.
cell-free measurements of PtEn activity
In vitro PTEN activity was evaluated in the presence of re-
combinant 2N4R-tau (obtained as described in Barthélemy 
et al., 2016) by monitoring the production of phosphatidy-
linositol 4,5 bisphosphate (PIP2) from phosphatidylinositol 
3,4,5 triphosphate (PIP3) by recombinant PTEN. Recom-
binant PTEN (Berlin Pharma) and tau protein or albumin as 
a control was incubated 1 h at 37°C in the presence of PIP3 
in low-bind 0.5-ml Eppendorf tubes. Then, the samples were 
exposed to an inactivating temperature of 95°C, and PIP2 
levels were determined using ELI SA (Echelon-Bioscience) 
according to the manufacturer’s instructions.
BiFc plasmids
For the BiFC assay, we generated fusions of our proteins of 
interest with Venus fluorescent protein fragments as previously 
described (Outeiro et al., 2008). In particular, we used a larger 
N-terminal fragment of Venus (VN), corresponding to amino 
acids 1 to 158, and a smaller C-terminal fragment (VC), corre-
sponding to amino acids 159 to 239. Tau and PTEN cDNA were 
cloned to the 3′ end of the VN fragment (VN-tau, VN-PTEN) 
and upstream of the VC fragment (tau-VC, PTEN-VC) by 
PCR using specific primers, including restriction enzyme sites 
AflII at the 5′ end and Xho1 at the 3′ end. The primers used 
were VN-tau: 5′-GCG CTT AAG ATG GCT GAG CCC CGC 
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CAG GAG TTC GAA GTG ATGG-3′ and 5′-CGC CTC GAG 
TCA CAA ACC ACC CTG CTT GGC CAG GGA GGC AGA 
AGA CACC-3′; tau-VC: 5′-GCG CTT AAG ATG GCT GAG 
CCC CGC CAG GAG TTC GAA GTG ATGG-3′ and 5′-CGC 
CTC GAG CAA ACC CTG CTT GGC CAG GGA GGC AGA 
CAC CTCG-3′; VN-PTEN: 5′-GGG CTT AAG ATG ACA 
GCC ATC ATC AAAG-3′ and 5′-CCC CTC GAG TCA GAC 
TTT TGT AAT TTG TGT ATGC-3; and PTEN-VC: 5′-GGG 
CTT AAG ATG ACA GCC ATC ATC AAAG-3′ and 5′-CCC 
CTC GAG GAC TTT TGT AAT TTG TGT ATG CTG ATC-3′.
PCR fragments were restriction digested and cloned 
into aSyn BiFC constructs (Outeiro et al., 2008; Gonçalves 
et al., 2010; Lázaro et al., 2014). HEK 293 cells were grown 
in Dulbecco’s modified Eagle’s medium (PAN Biotech) 
supplemented with 10% fetal calf serum and 1% peni-
cillin/streptomycin, at 37°C in 5% CO2. The cells were 
transfected 24 h after plating using Metafectene (Biontex 
Laboratories) according to the manufacturer’s instructions. 
48 h after transfection, cells were washed with PBS and 
fixed with PBS/4% paraformaldehyde. The cells were per-
meabilized with PBS/0.1% Triton X-100, blocked for 1 h 
with 1.5% BSA, and incubated overnight with the pri-
mary antibody for tau (HT7, MN1000, 1:1,000; Thermo 
Fisher Scientific). After three washes with PBS, the sec-
ondary antibody anti–mouse IgG conjugated to Alexa 
Fluor 555 (1:1,000, Thermo Fisher Scientific) was added 
for 1  h at room temperature. Cell nuclei were stained 
with Hoechst dye (Hoechst 33258; Molecular Probes). 
Fluorescent images were captured either using a micro-
scope (DMI 6000B; Leica Biosystems) or an automatic 
microscope (IX81-ZDC; Olympus). Venus and tau fluo-
rescence was quantified from 16 fields of cell images au-
tomatically collected with the Olympus microscope and 
analyzed by the ScanR software.
BrEt
PIP3 production was monitored as follows. 300,000 N1E115 
cells were transfected using lipofectamine 2000 with 700 ng 
Luc-Akt-PH cDNA (PH domain of Akt is fused to Renilla 
luciferase), 300 ng pEYFP-Mem cDNA (YFP-targeted to the 
plasma membrane), and either 500 ng pcDNA3-hTau46 or 
pcDNA3. Cells were preincubated for 10 min with coelen-
terazine and then stimulated with 5 nM insulin. PIP3 pro-
duction was monitored in real time using BRET as described 
previously (Pierre-Eugene et al., 2012).
Metabolic cages
Spontaneous feeding and locomotor activity (beam breaks/
hour) were measured using metabolic cages (Labmaster; 
TSE Systems). In brief, food intake and locomotor activ-
ity were monitored continuously for 24 h. Food intake was 
measured by the integration of weighing sensors fixed at the 
top of the cage from which the food containers were sus-
pended into the home cage. Locomotor activity was assessed 
using a metal frame placed around the cage. Evenly spaced 
infrared light beams are emitted along the x axis. Beam in-
terruptions caused by movements of the animals are sensed 
and registered at high resolution. The sensors for detection 
of movement operate efficiently under both light and dark 
phases, allowing continuous recording. Mice were housed 
individually and acclimated to the home cage for 72 h prior 
experimental measurements.
Biochemical plasma parameters
Plasma was collected at the tail vein after a 6-h fasting, 
and parameters were determined as follows. Blood glu-
cose was measured using the Accu-Chek Performa glu-
cometer (Roche). Plasma insulin and leptin were measured 
using ultrasensitive insulin ELI SA (Mercodia AB) and a 
mouse/rat leptin enzyme immunoassay kit (Spibio), respec-
tively. Total and high-density lipoprotein (HDL) choles-
terol as well as triglycerides were measured by enzymatic 
method using ready-to-use kits (Biomérieux). Non–HDL 
cholesterol levels were calculated by subtracting HDL 
from total cholesterol.
Glucose tolerance tests
Glucose tolerance was assessed using the intraperitoneal 
glucose tolerance test after a 6-h fast. 1 g/kg D(+)glucose 
(Sigma-Aldrich) was injected intraperitoneally. Blood glu-
cose was then measured at 0, 15, 30, 60, 90, and 120 min 
after injection.
Assessment of potential association between MAPt 
haplotypes and glycemic traits in European individuals
The MAPT SNP rs1052553 was selected because it is a tag-
SNP for the H1 and H2 haplotypes (Donnelly et al., 2010). 
The A (major) and G (minor) alleles of rs1052553 capture the 
H1 and H2 haplotypes, respectively. To examine the potential 
association of rs1052553 with glycemic traits in European 
subjects, the publicly available GWAS data contributed by 
the MAG IC (the Meta-Analyses of Glucose and Insulin-
related traits Consortium) investigators were downloaded 
from www .magicinvestigators .org (Saxena et al., 2010; 
Prokopenko et al., 2014).
Statistics
Results are expressed as mean ± SEM. Statistical analyses 
were performed using the Student’s t test and one- or two-
way ANO VA followed by a post-hoc Fisher’s least significant 
difference (LSD) test using GraphPad Prism Software. P- 
values less than 0.05 were considered significant.
online supplemental material
Fig. S1 shows additional metabolic indexes for tau KO 
mice. Fig. S2 shows peripheral metabolic changes in mice 
heterozygous for tau compared with WT and KO animals. 
Fig. S3 shows a model of regulation of insulin signaling 
by tau.
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